Compare LCID & KLRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCID | KLRA |
|---|---|---|
| Founded | 2007 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2020 | 2026 |
| Metric | LCID | KLRA |
|---|---|---|
| Price | $3.57 | $12.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 6 |
| Target Price | $7.39 | ★ $42.40 |
| AVG Volume (30 Days) | ★ 9.4M | 1.3M |
| Earning Date | 11-09-2026 | 11-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $595,271,000.00 | N/A |
| Revenue This Year | $14.22 | N/A |
| Revenue Next Year | $125.39 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.37 | $9.76 |
| 52 Week High | $19.47 | $23.82 |
| Indicator | LCID | KLRA |
|---|---|---|
| Relative Strength Index (RSI) | 41.12 | 52.61 |
| Support Level | $2.37 | $9.76 |
| Resistance Level | $4.44 | $19.15 |
| Average True Range (ATR) | 0.26 | 0.86 |
| MACD | 0.03 | 0.44 |
| Stochastic Oscillator | 43.24 | 82.09 |
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It offers its own geographically distributed retail and service locations through direct-to-consumer online and retail sales. It also boasts a product roadmap of future vehicle programs and technologies. It focuses on in-house hardware and software innovation, vertical integration, and a clean-sheet approach to engineering and design, which led to the development of the Lucid Air. The Lucid Air is a luxury sedan that redefines both the luxury car segment and the EV space. Its geographic segments include North America, the Middle East, and Other International.
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.